Genome Test for Blood Cancers Approved by Medicare & Medicaid
October 12, 2023 5:49AM CDT
This Wednesday, July 22, 2020, photo provided by C2N Diagnostics shows equipment in a lab that analyzes blood samples at the company’s facility in the Center for Emerging Technologies in St. Louis. C2N Diagnostics has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also raises concern about the accuracy and impact of such life-altering news. (Jerry Naunheim Jr./C2N Diagnostics via AP)
(MissouriNet) Medicare and Medicaid have approved a new test for two blood cancers that was developed by Washington University in St. Louis. Dr. Richard Cote at the School of Medicine says the test advances precision, or personalized, medicine for blood cancer treatment by identifying genetic changes in cancer cells…
“This test is a very sophisticated test which essentially looks at the entire genome of the cells that comprise certain types of blood cancers, and specifically those blood cancers are called myeloid blood cancers.”
Demand for this test is expected to skyrocket across the U.S. now that it’s going to be covered by Medicare. Cote hopes to expand the test to treat other kinds of cancers in the future.
